Our top pick for
Bio-Path Holdings, Inc is a biotechnology business based in the US. Bio-Path shares (BPTH) are listed on the NASDAQ and all prices are listed in US Dollars. Bio-Path employs 10 staff and has a market cap (total outstanding shares value) of 0.00.
|52-week range||$3.12 - $9.40|
|50-day moving average||$6.68|
|200-day moving average||$5.06|
|Wall St. target price||$12.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-6.19|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||$0|
|Return on assets TTM||-34.84%|
|Return on equity TTM||-60.2%|
|Market capitalisation||$40.9 million|
TTM: trailing 12 months
There are currently 233,129 Bio-Path shares held short by investors – that's known as Bio-Path's "short interest". This figure is 208.7% up from 75,517 last month.
There are a few different ways that this level of interest in shorting Bio-Path shares can be evaluated.
Bio-Path's "short interest ratio" (SIR) is the quantity of Bio-Path shares currently shorted divided by the average quantity of Bio-Path shares traded daily (recently around 1.2 million). Bio-Path's SIR currently stands at 0.19. In other words for every 100,000 Bio-Path shares traded daily on the market, roughly 190 shares are currently held short.
However Bio-Path's short interest can also be evaluated against the total number of Bio-Path shares, or, against the total number of tradable Bio-Path shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bio-Path's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Bio-Path shares in existence, roughly 30 shares are currently held short) or 0.0337% of the tradable shares (for every 100,000 tradable Bio-Path shares, roughly 34 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bio-Path.
Find out more about how you can short Bio-Path stock.
We're not expecting Bio-Path to pay a dividend over the next 12 months.
Bio-Path's shares were split on a 1:20 basis on 17 January 2019. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Bio-Path shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Bio-Path shares which in turn could have impacted Bio-Path's share price.
Over the last 12 months, Bio-Path's shares have ranged in value from as little as $3.12 up to $9.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bio-Path's is 2.0524. This would suggest that Bio-Path's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. The company is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.